Key Takeaway: Cognition Therapeutics has released its financial results for the second quarter of 2024, along with an update on its business and clinical activities. The report highlights key financial metrics and ongoing projects, although specific details on clinical advancements were not disclosed. This update is part of the company's regular reporting cycle.
Price reaction · baseline $0.582 (2024-08-07 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close
+0.5%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update